Market capitalization | $4.53m |
Enterprise Value | $1.13m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.83 |
P/S ratio (TTM) P/S ratio | 75.50 |
P/B ratio (TTM) P/B ratio | 1.74 |
Revenue growth (TTM) Revenue growth | -67.76% |
Revenue (TTM) Revenue | $60.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
3 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.06 0.06 |
65%
65%
|
|
Gross Profit | -0.03 -0.03 |
130%
130%
|
|
EBITDA | -12 -12 |
45%
45%
|
EBIT (Operating Income) EBIT | -12 -12 |
45%
45%
|
Net Profit | -7.99 -7.99 |
65%
65%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.
Head office | United States |
CEO | Pankaj Mohan |
Employees | 12 |
Founded | 2011 |
Website | www.sonnetbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.